BenevolentAI
by BenevolentAI
· Based in United Kingdom →
— AI Drug Discovery | AI Pharma
Contact for pricing
Overview
BenevolentAI is a clinical-stage biotechnology company that utilizes artificial intelligence (AI) and machine learning to accelerate drug discovery and development. [4, 8, 11, 14, 15] Its primary function is to identify novel disease targets and potential drug candidates by analyzing vast amounts of biomedical data. [1, 8, 15]
- What it does: The Benevolent Platform integrates diverse data types, including genomic, clinical, chemical data, and scientific literature, into a proprietary knowledge graph. [1, 2, 3, 8, 16] This platform uses AI and machine learning algorithms to uncover hidden patterns, generate hypotheses about disease mechanisms, and predict potential drug interactions. [1, 2, 6, 8, 9] It aims to streamline the upstream drug discovery process from disease understanding to target prioritization. [8]
- Who it is for: BenevolentAI’s tools are primarily for pharmaceutical researchers, scientists, and executives involved in drug discovery and development. [4, 9] The company focuses on various disease areas, including neurology, immunology, oncology, chronic kidney disease, idiopathic pulmonary fibrosis, ALS, Parkinson’s Disease, glioblastoma, and sarcopenia. [5, 8, 9, 12, 14, 17]
- How it fits a clinical or practice workflow: While not directly integrated into clinical practice workflows, BenevolentAI’s technology supports the early stages of drug development. It assists in identifying new therapeutic targets and repurposing existing drugs, which can eventually lead to new treatments for patients. [1, 2, 3, 5, 6, 13] Collaborations with pharmaceutical companies and research institutions demonstrate its role in informing and accelerating research pipelines. [3, 11, 16]
- Notable capabilities: Key capabilities include predictive modeling to forecast outcomes and identify promising research directions, hypothesis generation tools, and the ability to integrate and contextualize diverse biomedical data. [1, 2, 8] The platform’s iterative learning approach allows AI models to refine predictions as new data emerges. [2] BenevolentAI has also demonstrated success in identifying drug repurposing candidates. [3, 5, 6]
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Deep learning and machine learning for complex disease biology
- Proprietary knowledge graph and ontologies
- Data integration from diverse sources (scientific literature, patents, trials, omics)
- Predictive modeling for therapeutic outcomes and research directions
- Hypothesis generation for novel biological targets
- AI-driven drug target identification and discovery
- In-house drug pipeline development
- Collaborations with pharmaceutical companies
- Iterative learning and refinement of AI models
- Natural Language Processing (NLP) for extracting correlations from scientific literature
Use Cases
- Accelerating drug discovery and development
- Identifying novel therapeutic targets for various diseases
- Repurposing existing drugs for new indications
- Enhancing scientific understanding and collaboration
- Prioritizing compounds for further investigation
- Reducing time and cost in traditional drug discovery methods
What Physicians Need to Know
Molecule Screening Capability
BenevolentAI utilizes AI-powered virtual screening to analyze billion-scale compound libraries, identifying drug candidates in days rather than months. They also leverage AI chemistry design tools in combination with wet lab facilities to deliver small molecule drug development candidates.
Clinical Trial Matching
BenevolentAI's platform includes AI models that predict clinical trial success probability based on preclinical data and historical trial outcomes. They also collaborate with companies like Novartis to interrogate clinical trial and experimental data to stratify patients for more precise medicine targeting.
Real-World Evidence Analysis
The platform analyzes extensive clinical and real-world data to detect early safety signals and predict potential adverse events, enhancing drug safety monitoring and patient outcomes. They also integrate pseudonymized or anonymized patient-level data, including electronic health records, into their knowledge graph.
Genomic Data Integration
BenevolentAI's approach involves interrogating vast amounts of genomic, transcriptomic, and proteomic data. Their comprehensive knowledge graph incorporates and capitalizes on various orthogonal data modalities, including genetics, to build a detailed mechanistic representation of human disease. They also integrate single-cell 'omics data to gain insights into diseases and potential drug targets.
Literature Mining
BenevolentAI uses AI, including natural language processing (NLP) and large language models (LLM), to mine and analyze vast amounts of scientific literature, patents, and other biomedical information. This allows them to extract relationships and identify previously unknown correlations to inform drug discovery.
Target Identification
A core capability of BenevolentAI is using AI and machine learning to enhance the target identification process. Their platform interrogates a comprehensive knowledge graph to hypothesize novel biological targets of therapeutic value for various diseases. They have successfully identified novel targets that have entered the drug portfolios of partners like AstraZeneca.
Safety Signal Detection
BenevolentAI employs generative AI to enhance pharmacovigilance by analyzing extensive clinical and real-world data to detect early safety signals and predict potential adverse events, improving drug safety monitoring.
Collaboration Features
BenevolentAI actively engages in strategic collaborations with pharmaceutical companies like AstraZeneca and Merck, integrating their AI platform and scientific expertise with partners' data and disease knowledge to accelerate drug discovery. They also collaborate with organizations like DNDi for neglected diseases.
Publication Support
BenevolentAI's work, including their AI-predicted hypothesis for baricitinib as a COVID-19 treatment, has been published in peer-reviewed forums.
Physician Tip
Physicians should be aware that BenevolentAI's platform focuses on accelerating drug discovery and identifying novel therapeutic targets by integrating vast and diverse biomedical data. This can lead to the development of new treatment options, particularly for underserved diseases. The platform's ability to analyze real-world evidence and predict safety signals may contribute to improved drug safety profiles in the future. While not directly a clinical tool for patient care, its impact on the drug pipeline could eventually offer more targeted and effective therapies, potentially influencing treatment paradigms for various conditions.
BenevolentAI's platform is designed to integrate vast amounts of biomedical data from over 85 different sources, including scientific literature, clinical trial records, omics datasets, electronic health records, patents, and chemical libraries. They have established integrations with industry-standard platforms such as Dotmatics, CDD Vault, NVIDIA DGX, and AWS. The platform's knowledge graph is built to be interoperable and optimized for reuse, facilitating integration with other data sources and systems.
Details
| Category | Drug Discovery & Research |
| Pricing |
Contact for pricing
|
| Deployment | Cloud-based (Benevolent Platform) |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Unknown AI-estimated BenevolentAI's AI platform first identified baricitinib as a potential COVID-19 treatment in January 2020. This led to its Emergency Use Authorization (EUA) by the FDA in November 2020, and later a full FDA approval for treating COVID-19 in hospitalized adults. |
| Integrations | |
| EHR | Not specified |
| Specialties | Infectious Disease, Oncology, Rheumatology |
What the Web Says
BenevolentAI is an AI-driven drug discovery company that leverages artificial intelligence and machine learning to analyze vast amounts of biomedical data, identify potential drug targets, and accelerate the development of new medicines for complex diseases. The company aims to make the drug discovery process more cost and time-efficient. They have an in-house drug pipeline and also collaborate with pharmaceutical partners like AstraZeneca.
Overall: MixedStrengths
- Utilizes AI knowledge graphs, target discovery, drug repurposing, and precision medicine for professional use.
- Potential to significantly shorten the drug discovery timeline and reduce costs.
- Strong collaborations with major pharmaceutical companies like AstraZeneca, leading to successful target identification.
- Mission-driven to preserve human life and address untreated diseases.
- Positive company culture with friendly people and a focus on employee development.
- Platform is disease-agnostic and applicable across various therapeutic areas.
Limitations
- Recent organizational instability and a lack of a clear, reproducible, scalable delivery pipeline.
- No regulatory wins yet, leading to a credibility gap as most AI drug discovery firms lack FDA-approved therapeutics.
- Marketing materials may lack detailed public benchmarks for infrastructure and operational KPIs.
- Integrating partner data often requires custom professional services rather than plug-and-play connectors, adding cost.
- Experienced a significant drop in company valuation after a strategic shift to develop an in-house drug pipeline.
- Review coverage is effectively absent on platforms like G2 and Capterra, making it difficult to find third-party operational feedback.
Based on reviews from: Vaight AI, Reddit, Harvard Business School AI Institute, Indeed.com, EA Forum, The Silicon Review, Medium, G2, aiopenminds, RFP.wiki, Zippia, Slashdot, techUK
Last updated: 2026-07-27
Ratings & Reviews
Rate BenevolentAI
Press & Coverage
BenevolentAI
BenevolentAI unveils major strategic overhaul with return to original mission
BenevolentAI announced a significant strategic restructuring to refocus on its founding TechBio mission, emphasizing core technologies for drug discovery and development, and plans to delist from Euronext Amsterdam to extend its cash runway into 2027.
2024-12
Med City News
AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots
BenevolentAI is undergoing its second restructuring in less than two years, aiming to return to its original mission of partnering with biopharma companies and making its AI technologies available for drug R&D.
2024-12
FirstWord Pharma
BenevolentAI to cut nearly a third of staff, shutter US office in latest reset
BenevolentAI announced a restructuring initiative to reduce its headcount by about 30% and close its US office, aiming to trim cash burn and extend its runway into Q3 2025.
2024-04
pharmaphorum
BenevolentAI CEO steps down as founders make a comeback
Ju00f6rg Mu00f6ller stepped down as CEO of BenevolentAI after nine months, with co-founder Ken Mulvany named executive chairman, as the company seeks new leadership following a turbulent period of restructuring and R&D cuts.
2024-10
BenevolentAI
BenevolentAI announces further success with AstraZeneca collaboration as novel Heart Failure target selected
AstraZeneca has added a novel target for Heart Failure to its discovery portfolio through its collaboration with BenevolentAI, demonstrating the platform's applicability across multiple therapeutic areas.
2025-03
BenevolentAI
EGM Results announcement
BenevolentAI announced the results of its Extraordinary General Meeting.
2025-03
BenevolentAI
Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.u00e0 r.l. and Publication of Notice of Extraordinary General Meeting
BenevolentAI announced a proposed delisting via merger into Osaka Holdings S.u00e0 r.l. and published the notice for an Extraordinary General Meeting.
2025-02
Biology Digital News
BenevolentAI Holdings Ltd. Unveils Next-Gen Target Identification Engine for Pharmaceutical & Drug Development
BenevolentAI Holdings Ltd. launched its AI-powered drug discovery platform, aiming to accelerate drug discovery from target identification to clinical candidate selection in a market projected to reach $4.9 billion by 2028.
2026-02
Videos
Product demos, reviews, and walkthroughs for BenevolentAI.
Loading videos...
Frequently Asked Questions
BenevolentAI primarily focuses on accelerating drug discovery and development by using AI to analyze vast amounts of biomedical data, including scientific literature, clinical trials data, and patient-level data. While its direct application isn't in routine clinical practice for physicians, its work aims to bring new medicines to market faster and more cost-effectively, which ultimately benefits patients and the healthcare ecosystem.
BenevolentAI handles pseudonymized or anonymized patient-level data, including electronic health records and genetic data, and adheres to regulations like the DPA 2018, UK GDPR, and PECR for personal data. While BenevolentAI focuses on drug discovery, any AI tool used in clinical settings would need to comply with relevant healthcare regulations such as HIPAA in the US, ensuring data privacy and security.
BenevolentAI's system has shown limitations, such as a drug candidate failing to meet secondary efficacy measures in a Phase IIa study for atopic dermatitis. Additionally, its system has limited capability in discovering known molecules based solely on natural language processing from existing literature, and its protein-binding prediction networks are still in early-phase testing.
Yes, there are AI tools more directly applicable to clinical decision-making. Alternatives like Dr. Oracle, Vera Health, IatroX (for the UK), Elicit (for research), and MediSearch are designed for evidence-based decision support in clinical settings and cite their sources. Some startups are even developing AI that can make clinical decisions and renew prescriptions, though these are still in early stages and raise accountability concerns.
BenevolentAI does not publish a standard price list as its primary commercial model involves bespoke collaborations with pharmaceutical companies. These deals are structured with upfront payments, discovery and development milestones, and tiered royalties on net sales. While they have described scalable recurring models for smaller biotech customers, exact enterprise pricing and implementation fees are not publicly itemized.
Suggest an Edit →
| Last Verified: 2026-07-26 | First Added: 2026-07-26